Regeneron/Sanofi Announce FDA Approval Of Dupixent Indicated For Children Aged 1 Year And Older With Eosinophilic Esophagitis
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals has announced that the FDA has approved Dupixent for use in children aged 1 year and older with Eosinophilic Esophagitis, a chronic immune system disease. This approval could potentially expand the patient base for Dupixent, which is already used to treat several other allergic inflammatory diseases.
January 25, 2024 | 7:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Dupixent has received FDA approval for treatment of children with Eosinophilic Esophagitis, likely to boost its market reach and sales.
FDA approval of a drug typically leads to an increase in its marketability and sales potential. Given that Dupixent is now approved for a new age group, Regeneron can expect an expansion in its customer base and potentially increased revenue from this drug, which should have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100